Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries

References

• VirgiliGParravanoMEvansJRGordonILucenteforteEAnti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysisCochrane Database Syst R20176CD007419
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Guidelines GroupDiabetic Retinopathy GuidelinesLondonThe Royal College of Ophthalmologists20121147
   Google Scholar
• Diabetic Retinopathy Clinical Research NetworkElmanMJAielloLPRandomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology201011761064.e351077.e3520427088
   PubMed Web of Science ®Google Scholar
• MichaelidesMKainesAHamiltonRDA prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2Ophthalmology201011761078.e21086.e220416952
   PubMed Web of Science ®Google Scholar
• MassinPBandelloFGarwegJGSafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes Care201033112399240520980427
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMKhwajaAAREAD-2 Study GroupTwo-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyOphthalmology2010117112146215120855114
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthULangGEHolzFGRESTORE Extension Study GroupThree-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension studyOphthalmology201412151045105324491642
   PubMed Web of Science ®Google Scholar
• The RISE and RIDE research groupLong-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDEOphthalmology20132013202223706949
   PubMed Web of Science ®Google Scholar
• WellsJAGlassmanARAyalaARDiabetic Retinopathy Clinical Research NetworkAflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trialOphthalmology201612361351135926935357
   PubMed Web of Science ®Google Scholar
• DoDVSchmidt-ErfurthUGonzalezVHThe DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edemaOphthalmology201111891819182621546089
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDBoyerDda Vinci Study GroupOne-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edemaOphthalmology201211981658166522537617
   PubMed Web of Science ®Google Scholar
• BrownDMSchmidt-ErfurthUDoDVIntravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studiesOphthalmology2015122102044205226198808
   PubMed Web of Science ®Google Scholar
• HallerJABandelloFBelfortROzurdex Geneva Study GroupRandomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusionOphthalmology201011761134.e31146.e320417567
   PubMed Web of Science ®Google Scholar
• CallananDGGuptaSBoyerDSOzurdex PLACID Study GroupDexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edemaOphthalmology201312091843185123706947
   PubMed Web of Science ®Google Scholar
• CampochiaroPABrownDMPearsonAFAME Study GroupLong-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edemaOphthalmology20111184626.e2635.e221459216
   PubMed Web of Science ®Google Scholar
• GilliesMCSutterFKSimpsonJMLarssonJAliHZhuMIntravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trialOphthalmology200611391533153816828501
   PubMed Web of Science ®Google Scholar
• GilliesMCSimpsonJMGastonCFive-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edemaOphthalmology2009116112182218719796823
   PubMed Web of Science ®Google Scholar
• YilmazTWeaverCDGallagherMJIntravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic reviewOphthalmology2009116590291119410949
   PubMed Web of Science ®Google Scholar
• RossELHuttonDWSteinJDDiabetic Retinopathy, Clinical Research NetworkCost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness TrialJAMA Ophthalmol2016134888889627280850
   PubMed Web of Science ®Google Scholar
• RégnierSAMalcolmWHaigJXueWCost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspectiveClinicoecon Outcomes Res2015723524725999748
   PubMed Web of Science ®Google Scholar
• MitchellPAnnemansLGallagherMCost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trialBr J Ophthalmol201296568869322399690
   PubMed Web of Science ®Google Scholar
• World Bank Country and Lending Groups – World Bank Data Help Desk https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groupsAccessed November 8, 2018
   Google Scholar
• JonasJBHaylerJKPanda-JonasSIntravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathyBr J Ophthalmol20008491064106710966969
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• SpaideRRanibizumab according to need: a treatment for age-related macular degenerationAm J Ophthalmol2007143467968017386275
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• WeckerTEhlkenCBühlerAFive-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVBr J Ophthalmol2017101335335927215744
   PubMed Web of Science ®Google Scholar
• PayneJFWykoffCCClarkWLTREX-DME Study GroupRandomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year OutcomesOphthalmology20171241748127836430
   PubMed Web of Science ®Google Scholar
• SugimotoMIchioANunomeTKondoMTwo year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocolMedicine (Baltimore)20179616e640628422832
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research NetworkWellsJAGlassmanARAflibercept, bevacizumab, or ranibizumab for diabetic macular edemaN Engl J Med2015372131193120325692915
   PubMed Web of Science ®Google Scholar
• ElmanMJAyalaABresslerNMDiabetic Retinopathy Clinical Research NetworkIntravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial resultsOphthalmology2015122237538125439614
   PubMed Web of Science ®Google Scholar
• International Monetary Fund 2016 Available from: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)_per_capitaAccessed October 25, 2017
   Google Scholar
• Central Administration of Pharmaceutical Affairs (CAPA)Egyptian Drug Authority (EDA) – Ministry of Health and Population of Egypt Available from: http://www.eda.mohp.gov.egAccessed October 25, 2017
   Google Scholar
• BeerPMBakriSJSinghRJLiuWPetersGB3rdMillerMIntraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injectionOphthalmology2003110468168612689886
   PubMed Web of Science ®Google Scholar
• MachemerRSugitaGTanoYTreatment of intraocular pro-liferations with intravitreal steroidsTrans Am Ophthalmol Soc197977171180545825
   PubMedGoogle Scholar
• DanisRPCiullaTAPrattLMAnlikerWIntravitreal triamcinolone acetonide in exudative age-related macular degenerationRetina200020324425010872928
   PubMed Web of Science ®Google Scholar
• MartidisADukerJSGreenbergPBIntravitreal triamcinolone for refractory diabetic macular edemaOphthalmology2002109592092711986098
   PubMed Web of Science ®Google Scholar
• JonasJBIntravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseasesActa Ophthalmol Scand200583664566316396641
   PubMedGoogle Scholar
• KurzPASuhlerEBFlaxelCJInjectable intraocular corticosteroidsBeckerMDavisJSurgical Management of Inflammatory Eye DiseaseBerlin, HeidelbergSpringer2008116
   Google Scholar
• PeymanGAMoshfeghiDMIntravitreal triamcinolone acetonideRetina200424348849015187684
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research NetworkA randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edemaOphthalmology200811591447145918662829
   PubMed Web of Science ®Google Scholar
• ScottIUIpMSVanveldhuisenPCSCORE Study Research GroupA randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6Arch Ophthalmol200912791115112819752420
   PubMedGoogle Scholar
• JonasJBKreissigISöfkerADegenringRFIntravitreal injection of triamcinolone for diffuse diabetic macular edemaArch Ophthalmol20031211576112523885
   PubMed Web of Science ®Google Scholar
• JonasJBKreissigIDegenringRFIntravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusionGraefes Arch Clin Exp Ophthalmol2002240978278312271378
   PubMed Web of Science ®Google Scholar
• JonasJBKreissigIHuggerPSauderGPanda-JonasSDegenringRIntravitreal triamcinolone acetonide for exudative age related macular degenerationBr J Ophthalmol200387446246812642311
   PubMed Web of Science ®Google Scholar
• JonasJBDegenringRFKreissigIFriedemannTAkkoyunIExudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized studyEye (Lond)200519216317015218517
   PubMed Web of Science ®Google Scholar
• SpandauUHDerseMSchmitz-ValckenbergPPapoulisCJonasJBDosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedemaBr J Ophthalmol2005898999100316024853
   PubMed Web of Science ®Google Scholar
• European glaucoma societyTerminology and guidelines for glaucoma 4th edition – chapter 2: Classification and terminology Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and TerminologyBr J Ophthalmol201710157312728424171
   PubMed Web of Science ®Google Scholar
• LiFWenXZhangHFanXNovel insights into the role of long noncoding RNA in ocular diseasesInt J Mol Sci201617447827043545
   PubMed Web of Science ®Google Scholar
• ZhaoYXChenXWDiabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studiesInt J Ophthalmol20171091430143528944204
   PubMed Web of Science ®Google Scholar
• ChamABansalMBandaHKSecondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathyClin Ophthalmol2016101187119727390515
   PubMedGoogle Scholar
• ParkHYLJeonSLeeMYParkCKGlaucoma progression in the unaffected fellow eye of glaucoma patients who developed unilateral branch retinal vein occlusionAm J Ophthalmol201717519420027793602
   PubMed Web of Science ®Google Scholar
• García-ArumíJBoixaderaAGiraltJComparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal useBr J Ophthalmol20058991112111416113361
   PubMed Web of Science ®Google Scholar
• Rodriguez-ColemanHYuanPKimHIntravitreal injection of triamcinolone for diffuse macular edemaArch Ophthalmol200412271085108615249388
   PubMedGoogle Scholar